T. Andre

Final overall survival for the phase 3 KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer

Background In the phase 3, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab versus chemotherapy provided superior progression-free survival (PFS) at second interim a...

J. Bendell ;

D. Le ;

Takayuki Yoshino , MD, PhD;

W. Zhong ;

T. Andre ;

D. Fogelman ;

K. Shiu ;

P. Marinello ;

T. Kim ;

L. Diaz ;

B. Jensen ;

L. Jensen ;

C. Punt ;

D. Smith ;

Rocio Garcia-Carbonero , MD, PhD;

J. Garcia Alcaide ;

P. Gibbs ;

C. De la Fouchardiere ;

F. Herrero Rivera ;

E. Elez ;

07/02/2021

Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142

Background In the phase 2 multicohort CheckMate 142 study (NCT02060188), nivolumab plus low-dose (1 mg/kg) ipilimumab provided robust and durable clinical benefit with a manageable safety...

S. Abdullaev ;

A. Memaj ;

M. Lei ;

Scott Kopetz , MD, PhD;

M. Overman ;

A. Hill ;

K. Wong ;

T. Andre ;

Eric Van Cutsem , MD, PhD;

Sara Lonardi ;

H. Lenz ;

F. Gelsomino ;

M. Aglietta ;

M. Morse ;

Ryan M. McDermott ;

M. Sawyer ;

A. Hendlisz ;

B. Neyns ;

07/02/2021

A phase 3 study of nivolumab (NIVO), NIVO + ipilimumab (IPI), or chemotherapy for microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW

Background Patients with MSI-H/dMMR mCRC treated with chemotherapy have poorer outcomes than patients with microsatellite stable/MMR proficient mCRC. Pembrolizumab monot...

T. Andre ;

Sara Lonardi ;

S. Abdullaev ;

M. Lei ;

L. Jensen ;

C. De la Fouchardiere ;

E. Elez ;

J. Bennouna ;

G. Mendez ;

J. Li ;

Eric Van Cutsem , MD, PhD;

E. Goekkurt ;

T. Chen ;

Takayuki Yoshino , MD, PhD;

06/27/2022

Phase 2 study of pembrolizumab-based combination therapy in patients with microsatellite instability-high or mismatch repair-deficient stage IV colorectal cancer

Background The PD-1 inhibitor pembrolizumab has shown robust clinical activity in patients with mismatch repair-deficient or microsatellite instability-high (dMMR/MSI-H)...

M. Gumus ;

J. Bae Ahn ;

L. Wyrwicz ;

M. Kwiatkowski ;

J. Kim ;

S. Yalcin ;

M. Sendur ;

A. Odeleye-Ajakaye ;

P. Leconte ;

T. Andre ;

T. Kim ;

D. Fogelman ;

C. Sposetti ;

06/27/2022

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion gastrointestinal (GI) cancer: An updated analysis

BackgroundNeurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in various tumour types. Larotrectinib is a first-in-class, highly selective, central nervous s...

T. Andre ;

D. Hong ;

J. Deeken ;

A. Italiano ;

T. Liu ;

D. Burcoveanu ;

R. Norenberg ;

C. Mussi ;

R. Xu ;

A. Drilon ;

Liang Shen , PhD;

06/25/2023

Analysis of the immune-related endpoints of the mismatch repair–deficient non-endometrial solid cancers cohort from the GARNET study

Background Dostarlimab is a humanized monoclonal antibody that binds the programmed cell death protein 1 (PD-1) receptor and blocks interaction with its ligands PD-L1 and PD-L2. The GARNE...

D. Berton ;

T. Andre ;

G. Curigliano ;

H. Arkenau ;

J. Trigo ;

S. Ellard ;

V. Moreno ;

C. Abdeddaim ;

A. Anton ;

S. Kumar ;

W. Guo ;

E. Im ;